ERUZUN, H. Sclerosing cholangitis associated with dabrafenib–trametinib therapy: BRAF/MEK inhibitors should be considered. Journal of Gastrointestinal and Liver Diseases, [S. l.], v. 35, n. 1, p. 136–137, 2026. DOI: 10.15403/jgld-6698. Disponível em: https://www.jgld.ro/jgld/index.php/jgld/article/view/6698. Acesso em: 18 jul. 2026.